Who are Gemcitabine - 21 day cycle's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gemzar, HYDROXYUREA, Fludarabine (FLU), Platinum + Gemcitabine, standard dose ARA-C, Gemcitabine (GEM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemcitabine-21-day-cycle.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Gemcitabine - 21 day cycle — Competitive Intelligence Brief

Gemcitabine - 21 day cycle (Gemcitabine - 21 day cycle) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog. Area: Oncology.

phase 2 Nucleoside analog Ribonucleotide reductase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gemcitabine - 21 day cycle (Gemcitabine - 21 day cycle) — Actuate Therapeutics Inc.. Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gemcitabine - 21 day cycle TARGET	Gemcitabine - 21 day cycle	Actuate Therapeutics Inc.	phase 2	Nucleoside analog	Ribonucleotide reductase
Gemzar	Gemcitabine Hydrochloride	Accord Hlthcare	marketed	Nucleoside metabolic inhibitor	Ribonucleotide reductase; DNA incorporation	1996-01-01
HYDROXYUREA	HYDROXYUREA		marketed	Antimetabolite [EPC]	Ribonucleotide reductase	1967-01-01
Fludarabine (FLU)	Fludarabine (FLU)	Nanfang Hospital, Southern Medical University	marketed	Purine nucleoside analog	Ribonucleotide reductase, DNA polymerase
Platinum + Gemcitabine	Platinum + Gemcitabine	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Chemotherapy combination (platinum agent + nucleoside analog)	DNA (platinum crosslinking); ribonucleotide reductase and DNA polymerase (gemcitabine)
standard dose ARA-C	standard dose ARA-C	National Research Center for Hematology, Russia	marketed	Nucleoside analog antimetabolite	DNA polymerase; ribonucleotide reductase
Gemcitabine (GEM)	Gemcitabine (GEM)	Sun Yat-sen University	marketed	Nucleoside analog; antimetabolite	Ribonucleotide reductase; DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-06-28 — Gemzar · 12403086 · Formulation · US
2032-04-15 — Gemzar · 8679094 · Formulation · US
2033-07-01 — Gemzar · 9241948 · Formulation · US
2034-08-19 — Gemzar · 10729823 · Formulation · US
2034-08-19 — Gemzar · 12447241 · Formulation · US
2041-12-23 — HYDROXYUREA · 12409156 · Formulation · US

Sponsor landscape (Nucleoside analog class)

Third Affiliated Hospital, Sun Yat-Sen University · 2 drugs in this class
Actuate Therapeutics Inc. · 2 drugs in this class
City of Hope Medical Center · 1 drug in this class
Cooperative Study Group A for Hematology · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Innovent Biologics (Suzhou) Co. Ltd. · 1 drug in this class
Osaka Medical Center for Cancer and Cardiovascular Diseases · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class
The Methodist Hospital Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemcitabine - 21 day cycle — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-21-day-cycle. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab